Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Enspryng, satralizumab, Date of authorisation: 24/06/2021, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Pergoveris, follitropin alfa,lutropin alfa, Date of authorisation: 25/06/2007, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Pergoveris, follitropin alfa,lutropin alfa, Date of authorisation: 25/06/2007, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Date of authorisation: 20/11/2006, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Sprycel, dasatinib (anhydrous), Date of authorisation: 20/11/2006, Revision: 45, Status: Authorised

Human medicines European public assessment report (EPAR): Atazanavir Viatris (previously Atazanavir Mylan), atazanavir, Date of authorisation: 22/08/2016, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Atazanavir Viatris (previously Atazanavir Mylan), atazanavir, Date of authorisation: 22/08/2016, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Rezzayo, rezafungin, Date of authorisation: 22/12/2023, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Rezzayo, rezafungin, Date of authorisation: 22/12/2023, Revision: 1, Status: Authorised

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness